Drugs

, Volume 65, Issue 13, pp 1825–1849

Sulfasalazine

A Review of its Use in the Management of Rheumatoid Arthritis
Adis Drug Evaluation

Summary

Abstract

Sulfasalazine (salazosulfapyridine) [Azulfidine®, Salazopyrin®] is a well established disease-modifying antirheumatic drug (DMARD) used in the treatment of patients with rheumatoid arthritis. Clinical trials with sulfasalazine have used an array of measures of disease activity, such as the number of tender and swollen joints, Ritchie articular index (RAI) and erythrocyte sedimentation rate (ESR). In randomised, double-blind, placebo-controlled trials, sulfasalazine was associated with statistically significant benefits for various measures of disease activity, according to results of individual trials and/or meta-analysis. Sulfasalazine was associated with broadly similar efficacy to that of various other DMARDs in several randomised, double-blind, comparative trials. Promising results have also been demonstrated with sulfasalazine in combination with other DMARDs (e.g. methotrexate and hydroxychloroquine) in patients with early rheumatoid arthritis and in those with more established disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Sulfasalazine has a relatively short lag time until its onset of action and is often considered to be among the more efficacious traditional DMARDs. Based on considerations of safety, convenience and cost, many rheumatologists (particularly outside of the US) select sulfasalazine as initial therapy, although preferred first-line treatment options vary between countries.

Pharmacological Properties

The precise mechanism of action of sulfasalazine has not been fully elucidated, nor is it clear whether the parent drug and/or its main metabolites (sulfapyridine and mesalazine [mesalamine; 5-aminosalicylic acid]) are principally responsible for its beneficial effects in rheumatoid arthritis.

Among the pharmacodynamic effects demonstrated with sulfasalazine, sulfapyridine and/or mesalazine at clinically relevant concentrations in vitro are the inhibition of cytokine release (interleukin [IL]-1, IL-2, IL-6, IL-12 and tumour necrosis factor-α) and IgM and IgG production. Studies in animal models of autoimmune disease also support an immunomodulatory action of sulfasalazine, and proinflammatory cytokines were suppressed at the same time as measures of disease activity improved in patients with rheumatoid arthritis who received sulfasalazine.

Following oral administration of sulfasalazine, approximately 10–30% of the parent drug is absorbed from the small intestine, although systemic absorption in healthy Japanese volunteers is <10%. Sulfasalazine that reaches the large intestine is cleaved by bacterial azoreductases, thus releasing sulfapyridine and mesalazine. Sulfapyridine is almost completely absorbed compared with about 20–30% absorption for mesalazine.

All three moieties — sulfasalazine, sulfapyridine and mesalazine — are extensively metabolised. After multiple-dose administration of enteric-coated sulfasalazine, the mean elimination half-life (t1/2) of sulfasalazine (6.1–17.0 hours) and sulfapyridine (8.0–21.0 hours) in European patients with rheumatoid arthritis ranged widely, depending on patient age and/or acetylator phenotype. In healthy Japanese volunteers, t1/2 of sulfasalazine (3.0 hours) was somewhat shorter.

Therapeutic Efficacy in Rheumatoid Arthritis

Patients with rheumatoid arthritis who were treated for 6 months with entericcoated sulfasalazine 2 g/day had statistically significant improvements in the number of swollen and tender joints, RAI and ESR compared with placebo in a randomised, double-blind trial. The beneficial effects of sulfasalazine were confirmed in a meta-analysis of several placebo-controlled trials. In Japan, a large, double-blind, dose-finding study in patients with rheumatoid arthritis showed that the optimal dose of sulfasalazine is 1 g/day in Japanese patients.

When compared with other DMARDs in head-to-head comparisons of up to 1 year in duration, sulfasalazine (usually 2 g/day) had broadly similar clinical efficacy to that of methotrexate, leflunomide, hydroxychloroquine, penicillamine and intramuscular gold. Measures of disease activity evaluated in these randomised, double-blind trials typically included RAI, grip strength, duration of morning stiffness, ESR, pain, and the number of tender and swollen joints. Importantly, sulfasalazine has also been shown to retard radiographic progression of rheumatoid arthritis.

Two randomised, double-blind trials showed no clear advantage of combination therapy with sulfasalazine plus methotrexate over monotherapy with either agent in patients with early rheumatoid arthritis (duration <2 years). However, in another well conducted trial in this patient population, early aggressive therapy with sulfasalazine, methotrexate and hydroxychloroquine plus low-dose prednisolone was associated with significantly greater remission rates than sulfasalazine with or without prednisolone. Combination regimens, such as sulfasalazine, methotrexate and hydroxychloroquine, have also shown promising results in patients with refractory or long-standing rheumatoid arthritis.

Tolerability

Adverse gastrointestinal effects (e.g. nausea, vomiting, dyspepsia, anorexia), CNS effects (e.g. headache and dizziness) and rash are the most frequently reported adverse events associated with sulfasalazine. The use of enteric-coated sulfasalazine tablets has largely replaced the standard formulation of sulfasalazine in clinical practice, as the enteric-coated formulation markedly reduces the severity and incidence of adverse gastrointestinal effects.

Other adverse events associated with sulfasalazine include haematological disturbances (such as leukopenia) which occur in ≤3% of patients; less frequently reported problems include blood dyscrasias, hypersensitivity reactions, dyspnoea and hepatic dysfunction. In addition, apparently reversible oligospermia (or related conditions) occurs in male patients. Approximately 20–30% of patients with rheumatoid arthritis who are treated with sulfasalazine discontinue therapy because of adverse effects, approximately two-thirds of which involve the gastrointestinal tract or CNS.

References

  1. 1.
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001 Sep 15; 358: 903–11PubMedCrossRefGoogle Scholar
  2. 2.
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46: 328–46CrossRefGoogle Scholar
  3. 3.
    Smedegård G, Björk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995 Nov; 34 Suppl. 2: 7–15Google Scholar
  4. 4.
    Fujiwara M, Mitsui K, Yamamoto I. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn J Pharmacol 1990; 54(2): 121–31PubMedCrossRefGoogle Scholar
  5. 5.
    Hashimoto J, Sato K, Higaki M, et al. The effects of antirheumatic drugs on the production of, and the responsiveness to cytokines (IL-1 and IL-6). Drug Eval 1991 May; 11(3): 279–86Google Scholar
  6. 6.
    Kang BY, Chung SW, Im SY, et al. Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology 1999 Sep; 98(1): 98–103PubMedCrossRefGoogle Scholar
  7. 7.
    Rodenburg RJ, Ganga A, van Lent PL, et al. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 2000 Sep; 43(9): 1941–50PubMedCrossRefGoogle Scholar
  8. 8.
    Hirohata S, Ohshima N, Yanagida T, et al. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol 2002 Apr; 2(5): 631–40PubMedCrossRefGoogle Scholar
  9. 9.
    Comer SS, Jasin HE. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988 Apr; 15(4): 580–6PubMedGoogle Scholar
  10. 10.
    Imai F, Suzuki T, Ishibashi T, et al. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J Rheumatol 1994 Apr; 21(4): 612–5PubMedGoogle Scholar
  11. 11.
    Fener P, Bannwarth B, Gillet P, et al. Influence of sulfasalazine on established collagen arthritis in rats. Clin Exp Rheumatol 1990; 8: 167–70PubMedGoogle Scholar
  12. 12.
    Yamazaki T, Miyai E, Shibata H, et al. Pharmacological studies of salazosulfapyridine (SASP) evaluation of anti-rheumatic action [in Japanese]. Pharmacometrics 1991; 41(6): 563–74Google Scholar
  13. 13.
    Yamamoto I, Fujiwara M, Moriya K, et al. In vivo and in vitro suppression of the anti-DNA antibody production and improvement of autoimmune disease in NZB/W F1 and MRL/1 mice by salazosulfapyridine. Pharmacometrics 1991; 41(6): 591–6Google Scholar
  14. 14.
    Abe C, Miyazaki N, Arinishi M, et al. Effects of salazosulfapyridine on joint lesions in MRL/I mice. Int J Immunother 1991; 7(1): 9–14Google Scholar
  15. 15.
    Danis VA, Franic GM, Rathjen DA, et al. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis 1992 Aug; 51(8): 946–50PubMedCrossRefGoogle Scholar
  16. 16.
    Volin MV, Harlow LA, Woods JM, et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum 1999 Sep; 42(9): 1927–35PubMedCrossRefGoogle Scholar
  17. 17.
    Akahoshi T, Namai R, Sekiyama N, et al. Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J Leukoc Biol 1997 Dec; 62: 817–26PubMedGoogle Scholar
  18. 18.
    Pruzanski W, Stefanski E, Vadas P, et al. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol 1997 Jun 15; 53(12): 1901–7PubMedCrossRefGoogle Scholar
  19. 19.
    Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflammed sites. J Immunol 1996 Mar 1; 156: 1937–41PubMedGoogle Scholar
  20. 20.
    Matasic R, Dietz AB, Vuk-Pavlovic S. Maturation of human dendritic cells as sulfasalazine target. Croat Med J 2001 Aug; 42(4): 440–5PubMedGoogle Scholar
  21. 21.
    Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004 Dec; 50(12): 3831–43PubMedCrossRefGoogle Scholar
  22. 22.
    Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993 Nov; 25(5): 392–407PubMedCrossRefGoogle Scholar
  23. 23.
    Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995 Jul; 50: 137–56PubMedCrossRefGoogle Scholar
  24. 24.
    Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985; 10(4): 285–302PubMedCrossRefGoogle Scholar
  25. 25.
    Uchida E, Kai K, Kobayashi S, et al. A study of pharmacokinetics and safety of salazosulfapyridine enteric coated tablet (PJ-306) in healthy Japanese subjects [in Japanese]. Jpn J Clin Pharmacol Ther 1990 Jun; 21(2): 377–89CrossRefGoogle Scholar
  26. 26.
    Astbury C, Taggart AJ, Juby L, et al. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease. Ann Rheum Dis 1990 Aug; 49(8): 587–90PubMedCrossRefGoogle Scholar
  27. 27.
    Pharmacia & Upjohn Company. Azulfidine EN-tabs® (sulfasalazine delayed release tablets, USP) prescribing information. Kalamazoo (MI): Pharmacia & Upjohn Company, 2001 SepGoogle Scholar
  28. 28.
    Taggart AJ, McDermott B, Delargy M, et al. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. Scand J Rheumatol Suppl 1987; 64: 29–36PubMedCrossRefGoogle Scholar
  29. 29.
    Taggart AJ, McDermott BJ, Roberts SD. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. Clin Pharmacokinet 1992 Oct; 23(4): 311–20PubMedCrossRefGoogle Scholar
  30. 30.
    Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002 Dec; 29: 2492–9PubMedGoogle Scholar
  31. 31.
    Ohtani T, Hiroi A, Sakurane M, et al. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. Br J Dermatol 2003 May; 148(5): 1035–9PubMedCrossRefGoogle Scholar
  32. 32.
    Haagsma CJ, Russel FGM, Vree TB, et al. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 1996 Aug; 42: 195–200PubMedCrossRefGoogle Scholar
  33. 33.
    Suarez-Almazor ME, Belseck E, Shea B, et al. Sulfasalazine for treating rheumatoid arthritis (review). Cochrane Database Syst Rev 2000; (2): CD000958Google Scholar
  34. 34.
    Ebringer R, Ahern M, Thomas D, et al., on behalf of the Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992; 19(11): 1672–7Google Scholar
  35. 35.
    Farr M, Waterhouse L, Johnson AE, et al. A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. Clin Rheumatol 1995 Sep; 14: 531–6PubMedCrossRefGoogle Scholar
  36. 36.
    Hannonen P, Mottonen T, Hakola M, et al. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993 Nov; 36(11): 1501–9PubMedCrossRefGoogle Scholar
  37. 37.
    Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988 Jun; 31(6): 702–13PubMedCrossRefGoogle Scholar
  38. 38.
    Nishioka N, Nobunaga M, Sakuma A. Comparison of sulfasalazine and placebo in a randomized, double-blind controlled dose-finding study in patients with rheumatoid arthritis [in Japanese]. Ryumachi 1991 Jun; 31(3): 327–45PubMedGoogle Scholar
  39. 39.
    Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999 Apr; 58: 220–5PubMedCrossRefGoogle Scholar
  40. 40.
    Haagsma CJ, van Riel PLCM, de Jong AJL, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997 Oct; 36: 1082–8PubMedCrossRefGoogle Scholar
  41. 41.
    Faarvang KL, Egsmose C, Kryger P, et al. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis 1993 Oct; 52(10): 711–5PubMedCrossRefGoogle Scholar
  42. 42.
    Nuver-Zwart IH, van Riel PL, van de Putte LB, et al. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989 May; 48(5): 389–95PubMedCrossRefGoogle Scholar
  43. 43.
    Neumann VC, Grindulis KA, Hubball S, et al. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J (Clin Res Ed) 1983 Oct 15; 287(6399): 1099–102CrossRefGoogle Scholar
  44. 44.
    Carroll GJ, Will RK, Breidahl PD, et al. Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. Rheumatol Int 1989; 8(6): 251–5PubMedCrossRefGoogle Scholar
  45. 45.
    van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989 May 13; 1(8646): 1036–8PubMedCrossRefGoogle Scholar
  46. 46.
    Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999 Jan 23; 353: 259–66PubMedCrossRefGoogle Scholar
  47. 47.
    Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997 Aug 2; 350: 309–18PubMedCrossRefGoogle Scholar
  48. 48.
    Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999 May 8; 353: 1568–73PubMedCrossRefGoogle Scholar
  49. 49.
    Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Van Zeben D, et al. Treatment strategies in early rheumatoid arthritis: clinical and radiological outcomes after 2 year follow-up of the Best study [abstract no. L4]. Arthritis Rheum 2004 Dec; 50(12): 4096Google Scholar
  50. 50.
    Nishiya K, Hisakawa N, Tahara K, et al. Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial. Acta Med Okayama 1999 Dec; 53(6): 275–9PubMedGoogle Scholar
  51. 51.
    Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002 Aug; 41: 892–8CrossRefGoogle Scholar
  52. 52.
    O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996 May 16; 334: 1287–91CrossRefGoogle Scholar
  53. 53.
    Nagaoka S, Ohno M, Sekiguchi A. Effects of sulfasalazine added to methotrexate therapy on RA patients in refractory and escaped cases. Clin Rheumatol 2003; 15: 220–6Google Scholar
  54. 54.
    Singh A, Appel AM, Kvien TK. Results of patient-reported outcomes from a double-blind study of etanercept and sulphasalazine, alone and combined, in patients with active rheumatoid arthritis [abstract no. SAT0245]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 355–6. Plus poster presented at European League Against Rheumatism Annual Congress of Rheumatology; 2003 Jun 18–21; LisbonGoogle Scholar
  55. 55.
    Haagsma CJ, van Riel PLCM, van de Putte LB. Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Br J Rheumatol 1995 Nov; 34 Suppl. 2: 104–8Google Scholar
  56. 56.
    O’Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 May; 46: 1164–70CrossRefGoogle Scholar
  57. 57.
    Hamada Y, Shinomiya F, Okada M, et al. Usefulness of three-drug additional combination therapy with bucillamine, sulfasalazine and methotrexate for refractory rheumatoid arthritis. Int J Immunother 2002; 18(2): 57–64Google Scholar
  58. 58.
    Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004 Jul; 63(7): 797–803PubMedCrossRefGoogle Scholar
  59. 59.
    Ciconelli RM, Ferraz MB, Visioni RA, et al. A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Br J Rheumatol 1996 Feb; 35: 150–4PubMedCrossRefGoogle Scholar
  60. 60.
    Svensson B, Ahlmen M, Forslind K, et al. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. Clin Exp Rheumatol 2003; 21: 327–32PubMedGoogle Scholar
  61. 61.
    Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968 Jul; 37(147): 393–406PubMedGoogle Scholar
  62. 62.
    Salaffi F, Peroni M, Ferraccioli GF. Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the chronic arthritis systemic index, disease activity score and Thompson’s articular index. Rheumatology (Oxford) 2000; 39: 90–6CrossRefGoogle Scholar
  63. 63.
    Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992 Oct; 35(10): 1117–25PubMedCrossRefGoogle Scholar
  64. 64.
    Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990 Oct; 33(10): 1449–61PubMedCrossRefGoogle Scholar
  65. 65.
    Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003 Jan; 42(1): 6–13CrossRefGoogle Scholar
  66. 66.
    Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 1999 Oct; 26: 2123–30PubMedGoogle Scholar
  67. 67.
    Kalden JR, Scott DL, Smolen JS, et al. Improved functional ability in patients with rheumatoid arthritis: longterm treatment with leflunomide versus sulfasalazine. J Rheumatol 2001 Sep; 28: 1983–91PubMedGoogle Scholar
  68. 68.
    Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001 Oct; 60: 913–23PubMedCrossRefGoogle Scholar
  69. 69.
    Larsen A, Kvien TK, Schattenkirchner M, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001; 30(3): 135–42PubMedCrossRefGoogle Scholar
  70. 70.
    Porter D, Madhok R, Hunter JA, et al. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. Ann Rheum Dis 1992 Apr; 51(4): 461–4PubMedCrossRefGoogle Scholar
  71. 71.
    Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000 Sep; 39: 975–81CrossRefGoogle Scholar
  72. 72.
    Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, et al. Disappointing longterm results with disease modifying antirheumatic drugs: a practice based study. J Rheumatol 1999 Nov; 26: 2337–43PubMedGoogle Scholar
  73. 73.
    McEntegart A, Porter D, Capell HA, et al. Sulfasalazine has a better efficacy/toxicity profile than auranofin: evidence from a 5 year prospective, randomized trial. J Rheumatol 1996 Nov; 23: 1887–90PubMedGoogle Scholar
  74. 74.
    Choy EHS, Scott DL, Kingsley GH, et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 2002; 20: 351–8PubMedGoogle Scholar
  75. 75.
    van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up [letter]. Lancet 1990 Mar 3; 335(8688): 539PubMedCrossRefGoogle Scholar
  76. 76.
    Maillefert JF, Combe B, Goupille P, et al. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis 2003 Aug; 62(8): 764–6PubMedCrossRefGoogle Scholar
  77. 77.
    Landewe RBM, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002 Feb; 46: 347–56PubMedCrossRefGoogle Scholar
  78. 78.
    Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24(10): 1308–15PubMedCrossRefGoogle Scholar
  79. 79.
    Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002 Apr; 46(4): 894–8PubMedCrossRefGoogle Scholar
  80. 80.
    Neva MH, Kauppi MJ, Kautiainen H, et al. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis Rheum 2000 Nov; 43: 2397–401PubMedCrossRefGoogle Scholar
  81. 81.
    Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004 Jul; 50(7): 2072–81PubMedCrossRefGoogle Scholar
  82. 82.
    Puolakka K, Kautiainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004 Jan; 50(1): 55–62PubMedCrossRefGoogle Scholar
  83. 83.
    Calguneri M, Pay S, Caliskaner Z, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 699–704PubMedGoogle Scholar
  84. 84.
    Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986 Aug 16; 293(6544): 420–3CrossRefGoogle Scholar
  85. 85.
    Abramson J, James DS, McManus JP, et al. Amelioration of sulfasalazine-associated gastric intolerance by use of enteric-coated tablets. Pract Gastroenterol 1988; 12(2): 32–9Google Scholar
  86. 86.
    Marmor D. The effects of sulphasalazine on male fertility. Reprod Toxicol 1995; 9: 219–23PubMedCrossRefGoogle Scholar
  87. 87.
    Donovan S, Hawley S, MacCarthy J, et al. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study. Br J Rheumatol 1990 Jun; 29(3): 201–4PubMedCrossRefGoogle Scholar
  88. 88.
    Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000 Mar 13; 160(5): 610–9PubMedCrossRefGoogle Scholar
  89. 89.
    British Society for Rheumatology. BSR guideline on standards of care for persons with rheumatoid arthritis [online]. Available from URL: http://www.msecportal.org/portal/editorial/PublicPages/bsr/536883013/FinalRAStandards.pdf [Accessed 2005 May 4]
  90. 90.
    British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary [online]. Available from URL: http://www.bnf.org [Accessed 2005 Mar 17]
  91. 91.
    Kawai S. Current drug therapy for rheumatoid arthritis. J Orthop Sci 2003; 8(2): 259–63PubMedCrossRefGoogle Scholar
  92. 92.
    Santen. Azulfidine® (salazosulfapyridine) EN tablets: prescribing information. Japan: Santen, 2005Google Scholar
  93. 93.
    van Jaarsveld CHM, Jacobs JWG, van der Veen MJ, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 2000 Jun; 59: 468–77PubMedCrossRefGoogle Scholar
  94. 94.
    British Society for Rheumatology. National guidelines for the monitoring of second line drugs [online]. Available from URL: http://www.rheumatology.org.uk [Accessed 2005 May 5]
  95. 95.
    Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66PubMedCrossRefGoogle Scholar
  96. 96.
    Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001 Apr 17; 134(8): 695–706PubMedGoogle Scholar
  97. 97.
    Jobanputra P, Wilson J, Douglas K, et al. A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford) 2004 Feb; 43(2): 206–10CrossRefGoogle Scholar
  98. 98.
    Garrood T, Scott DL. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Biodrugs 2001; 15(8): 543–61PubMedCrossRefGoogle Scholar
  99. 99.
    Goekoop YP, Allaart CF, Breedveld FC, et al. Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001 May; 13(3): 177–83PubMedCrossRefGoogle Scholar
  100. 100.
    Choy EH. Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2004 Oct; 43(10): 1205–7CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International LimitedMairangi BayNew Zealand

Personalised recommendations